Does GGPeps issue lot-specific documentation, or a batch certificate?

I have both a purity figure and a content figure, which is why the discrepancy is visible.

I want to understand what this actually establishes, as opposed to what it is being used to imply.

My concern is that I am being invited to draw a conclusion the data does not support.

What is the correct interpretation, and what is the common misreading?

Start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Specifically, a statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

Assume segregation is possible, and design your sampling to catch it if it exists.

edited 26 Jan 2026 by h_pergande — corrected a unit error in the worked example

It helps to be literal here: sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

If testing multiple vials, state how many you tested and why you chose those vials.

The part that matters: if a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.

If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

Most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

Assume segregation is possible, and design your sampling to catch it if it exists.